Literature DB >> 32778891

MolAICal: a soft tool for 3D drug design of protein targets by artificial intelligence and classical algorithm.

Qifeng Bai1, Shuoyan Tan1, Tingyang Xu2, Huanxiang Liu1, Junzhou Huang3, Xiaojun Yao1.   

Abstract

Deep learning is an important branch of artificial intelligence that has been successfully applied into medicine and two-dimensional ligand design. The three-dimensional (3D) ligand generation in the 3D pocket of protein target is an interesting and challenging issue for drug design by deep learning. Here, the MolAICal software is introduced to supply a way for generating 3D drugs in the 3D pocket of protein targets by combining with merits of deep learning model and classical algorithm. The MolAICal software mainly contains two modules for 3D drug design. In the first module of MolAICal, it employs the genetic algorithm, deep learning model trained by FDA-approved drug fragments and Vinardo score fitting on the basis of PDBbind database for drug design. In the second module, it uses deep learning generative model trained by drug-like molecules of ZINC database and molecular docking invoked by Autodock Vina automatically. Besides, the Lipinski's rule of five, Pan-assay interference compounds (PAINS), synthetic accessibility (SA) and other user-defined rules are introduced for filtering out unwanted ligands in MolAICal. To show the drug design modules of MolAICal, the membrane protein glucagon receptor and non-membrane protein SARS-CoV-2 main protease are chosen as the investigative drug targets. The results show MolAICal can generate the various and novel ligands with good binding scores and appropriate XLOGP values. We believe that MolAICal can use the advantages of deep learning model and classical programming for designing 3D drugs in protein pocket. MolAICal is freely for any nonprofit purpose and accessible at https://molaical.github.io.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 de novo drug design; GCGR; SARS-CoV-2 main protease; artificial intelligence; drug design; virtual screening

Year:  2021        PMID: 32778891      PMCID: PMC7454275          DOI: 10.1093/bib/bbaa161

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  25 in total

1.  Systemic evolutionary chemical space exploration for drug discovery.

Authors:  Chong Lu; Shien Liu; Weihua Shi; Jun Yu; Zhou Zhou; Xiaoxiao Zhang; Xiaoli Lu; Faji Cai; Ning Xia; Yikai Wang
Journal:  J Cheminform       Date:  2022-04-01       Impact factor: 5.514

Review 2.  Recent Advances in Application of Computer-Aided Drug Design in Anti-Influenza A Virus Drug Discovery.

Authors:  Dahai Yu; Linlin Wang; Ye Wang
Journal:  Int J Mol Sci       Date:  2022-04-25       Impact factor: 6.208

3.  Folic acid: a potential inhibitor against SARS-CoV-2 nucleocapsid protein.

Authors:  Yu-Meng Chen; Jin-Lai Wei; Rui-Si Qin; Jin-Ping Hou; Guang-Chao Zang; Guang-Yuan Zhang; Ting-Ting Chen
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

4.  D3AI-CoV: a deep learning platform for predicting drug targets and for virtual screening against COVID-19.

Authors:  Yanqing Yang; Deshan Zhou; Xinben Zhang; Yulong Shi; Jiaxin Han; Liping Zhou; Leyun Wu; Minfei Ma; Jintian Li; Shaoliang Peng; Zhijian Xu; Weiliang Zhu
Journal:  Brief Bioinform       Date:  2022-05-13       Impact factor: 13.994

5.  Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries.

Authors:  Yosef Masoudi-Sobhanzadeh; Aysan Salemi; Mohammad M Pourseif; Behzad Jafari; Yadollah Omidi; Ali Masoudi-Nejad
Journal:  Brief Bioinform       Date:  2021-11-05       Impact factor: 11.622

6.  Exploring the Distinct Binding and Activation Mechanisms for Different CagA Oncoproteins and SHP2 by Molecular Dynamics Simulations.

Authors:  Quan Wang; Wen-Cheng Zhao; Xue-Qi Fu; Qing-Chuan Zheng
Journal:  Molecules       Date:  2021-02-05       Impact factor: 4.411

7.  Molecular Structure, In Vitro Anticancer Study and Molecular Docking of New Phosphate Derivatives of Betulin.

Authors:  Elwira Chrobak; Maria Jastrzębska; Ewa Bębenek; Monika Kadela-Tomanek; Krzysztof Marciniec; Małgorzata Latocha; Roman Wrzalik; Joachim Kusz; Stanisław Boryczka
Journal:  Molecules       Date:  2021-01-31       Impact factor: 4.411

Review 8.  Advances in de Novo Drug Design: From Conventional to Machine Learning Methods.

Authors:  Varnavas D Mouchlis; Antreas Afantitis; Angela Serra; Michele Fratello; Anastasios G Papadiamantis; Vassilis Aidinis; Iseult Lynch; Dario Greco; Georgia Melagraki
Journal:  Int J Mol Sci       Date:  2021-02-07       Impact factor: 5.923

9.  Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations.

Authors:  Quan Wang; Wen-Cheng Zhao; Xue-Qi Fu; Qing-Chuan Zheng
Journal:  Front Chem       Date:  2020-11-23       Impact factor: 5.221

10.  The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis.

Authors:  Krzysztof Marciniec; Artur Beberok; Stanisław Boryczka; Dorota Wrześniok
Journal:  Pharmacol Rep       Date:  2021-05-30       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.